Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.84 |
| ▸ | EGFR | P00533 | 3/20 | 0.84 |
| ▸ | RET | P07949 | 9/20 | 0.72 |
| ▸ | KIT | P10721 | 4/20 | 0.72 |
| ▸ | CSF1R | P07333 | 2/20 | 0.72 |
| ▸ | ABL1 | P00519 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6184307 | 0.88 | BRAF (0.82) | BRAFEGFRRETKITCSF1R | |
| SCHEMBL29562470 | 0.88 | BRAF (0.82) | BRAFEGFRRETKITCSF1R | |
| SCHEMBL13771723 | 0.87 | RET (0.83) | BRAFEGFRRETKITCSF1R | |
| SCHEMBL26215023 | 0.85 | EGFR (0.64) | BRAFEGFRRETKITCSF1R | |
| SCHEMBL30080789 | 0.84 | BRAF (0.74) | BRAFEGFRRETKITCSF1R | |
| SCHEMBL19471824 | 0.84 | BRAF (0.74) | BRAFEGFRRETKITCSF1R | |
| SCHEMBL13765778 | 0.84 | KIT (1.00) | RETKITCSF1RABL1 | |
| SCHEMBL31620860 | 0.84 | BRAF (0.80) | BRAFEGFRRETKITCSF1R | |
| SCHEMBL589012 | 0.83 | KIT (0.75) | BRAFEGFRRETKITCSF1R | |
| SCHEMBL7544775 | 0.83 | RAB9A (0.62) | BRAFEGFRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024158759-A2 | INHIBITORS OF SOLVENT FRONT MUTATED RET KINASE | PURDUE RESEARCH FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| US-20250243203-A1 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | PURDUE RESEARCH FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| CN-119451675-A | Nicotinamide and benzamide based compounds, conjugates and compositions as inhibitors of translation and transcription related kinases | 普渡研究基金会 | 2025-02-14 | — | — | CN | disclosed |
| EP-4504174-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | Purdue Research Foundation (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024158759-A2 | INHIBITORS OF SOLVENT FRONT MUTATED RET KINASE | PURDUE RESEARCH FOUNDATION (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2023196930-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | PURDUE RESEARCH FOUNDATION (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243203-A1 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | NADK, NAMPT, NNMT | BRAF 127/4885EGFR 2318/4885RET 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.